InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U) (TASE:INCR) released preliminary financial results for the second quarter of 2022, revealing record revenue estimated to be CA$36 million ($27,86 million), more than double the revenues of the second quarter of 2021 and representing sequential growth of over 9%.
Preliminary Q2 2022 Financial Highlights and Milestones
Tenth consecutive quarter of high growth representing an annualized run rate of CA$143 million.
Company expects continued increases in revenues during the third quarter of 2022.
Sustained market share growth due to solid demand for Canndoc's branded products and …